Protein palmitoylation is a post-translational modification that involves the addition of a 16-carbon saturated fatty acid, typically palmitate (C16:0), to cysteine residues within target proteins.
U.S. health authorities expedite assessment of Patritumab Deruxtecan for select cases of advanced or widespread EGFR-altered Non-Small Cell Lung Cancer after first treatments.
Zenyaku Kogyo Co., Ltd. and Chugai Pharmaceutical Co., Ltd. have announced obtaining approval from Japan's Ministry of Health, Labour and Welfare to commercially distribute Rituxan®.
Mineralys Therapeutics Reports Initial Participant Receives Dose in Start-HTN, Their Second Major Study of Lorundrostat Aimed at Hypertension Management.
Jazz Pharmaceuticals plc announced early results from its Phase 2 trial evaluating the efficacy and safety of JZP150, a selective FAAH enzyme inhibitor, in adults with PTSD.